Commonwealth Equity Services
NBIX icon

Commonwealth Equity Services’s Neurocrine Biosciences NBIX Stock Holding History

Commonwealth Equity Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.57M Sell
15,270
-86
-0.6% -$12.8K ﹤0.01% 1893
2026
Q1 		$2.02M Buy
15,356
+855
+6% +$113K ﹤0.01% 2005
2025
Q4 		$2.06M Buy
14,501
+178
+1% +$25.8K ﹤0.01% 1964
2025
Q3 		$2.01M Buy
14,323
+222
+2% +$30.1K ﹤0.01% 1979
2025
Q2 		$1.77M Buy
14,101
+390
+3% +$44.7K ﹤0.01% 2082
2025
Q1 		$1.52M Sell
13,711
-245
-2% -$31K ﹤0.01% 2131
2024
Q4 		$1.91M Sell
13,956
-1,320
-9% -$163K ﹤0.01% 1904
2024
Q3 		$1.76M Buy
15,276
+360
+2% +$49.4K ﹤0.01% 1897
2024
Q2 		$2.05M Buy
14,916
+975
+7% +$134K ﹤0.01% 1770
2024
Q1 		$1.92M Buy
13,941
+84
+0.6% +$11.5K ﹤0.01% 1816
2023
Q4 		$1.83M Sell
13,857
-150
-1% -$17.3K ﹤0.01% 1758
2023
Q3 		$1.58M Sell
14,007
-1,097
-7% -$116K ﹤0.01% 1769
2023
Q2 		$1.42M Sell
15,104
-234
-2% -$22.9K ﹤0.01% 1858
2023
Q1 		$1.55K Buy
15,338
+200
+1% +$20.8K ﹤0.01% 1726
2022
Q4 		$1.81M Buy
15,138
+440
+3% +$51.5K ﹤0.01% 1563
2022
Q3 		$1.56M Sell
14,698
-1,809
-11% -$184K ﹤0.01% 1593
2022
Q2 		$1.61M Sell
16,507
-2,138
-11% -$197K ﹤0.01% 1564
2022
Q1 		$1.75M Buy
18,645
+182
+1% +$15.4K ﹤0.01% 1589
2021
Q4 		$1.57M Sell
18,463
-342
-2% -$31.5K ﹤0.01% 1659
2021
Q3 		$1.8M Sell
18,805
-1,375
-7% -$130K ﹤0.01% 1494
2021
Q2 		$1.96M Buy
20,180
+537
+3% +$51.5K 0.01% 1426
2021
Q1 		$1.91M Sell
19,643
-1,221
-6% -$128K 0.01% 1348
2020
Q4 		$2M Sell
20,864
-3,278
-14% -$317K 0.01% 1231
2020
Q3 		$2.32M Buy
24,142
+217
+0.9% +$25.1K 0.01% 1011
2020
Q2 		$2.92M Buy
23,925
+705
+3% +$77.9K 0.01% 831
2020
Q1 		$2.01M Buy
23,220
+265
+1% +$25.9K 0.01% 896
2019
Q4 		$2.47M Buy
22,955
+8,721
+61% +$913K 0.01% 924
2019
Q3 		$1.28M Sell
14,234
-232
-2% -$21.7K 0.01% 1209
2019
Q2 		$1.22M Sell
14,466
-576
-4% -$47.3K 0.01% 1231
2019
Q1 		$1.32M Buy
15,042
+4,665
+45% +$390K 0.01% 1126
2018
Q4 		$741K Sell
10,377
-681
-6% -$65.2K ﹤0.01% 1382
2018
Q3 		$1.36M Buy
11,058
+8,989
+434% +$1.02M 0.01% 1130
2018
Q2 		$203K Buy
+2,069
New +$185K ﹤0.01% 2453

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Commonwealth Equity Services's NBIX Position: Q2 2026 in Review

Commonwealth Equity Services reduced its Neurocrine Biosciences (NBIX) stake by 0.56% in Q2 2026, selling an estimated $12.8K and leaving 15,270 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1893.

Commonwealth Equity Services first reported a position in NBIX in Q2 2018 and has held it in 33 quarters since. The position peaked at $2.92M in Q2 2020. 260 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Commonwealth Equity Services held 15,270 shares of Neurocrine Biosciences worth $2.57M as of Q2 2026.
  • Commonwealth Equity Services sold 86 Neurocrine Biosciences shares in Q2 2026, an estimated $12.8K.
  • Neurocrine Biosciences made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #1893 holding.
  • Commonwealth Equity Services first reported a position in Neurocrine Biosciences in Q2 2018 and has held it in 33 quarters since.
  • Commonwealth Equity Services's Neurocrine Biosciences position peaked at $2.92M in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.